Cozzio Antonio, Kempf Werner, Schmid-Meyer Regula, Gilliet Michel, Michaelis Sonja, Schärer Leo, Burg Günter, Dummer Reinhard
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
Leuk Lymphoma. 2006 May;47(5):865-9. doi: 10.1080/10428190500399698.
Primary cutaneous marginal zone lymphomas (pcMZL) belong to the primary cutaneous B-cell lymphoma (pCBCL) group. They are characterized by their restriction to the skin and a high likelihood of recurrence after various treatment modalities. First-line therapy consists of surgery and radiotherapy. These therapies may not always be indicated in young patients or in patients with pCBCL located in the face, where surgery or radiotherapy may leave disfiguring scars or radioderma. Eight patients with pcMZL were treated with intra-lesional injections of 3 million units of recombinant IFNalpha2a three times per week. The patients either did not want to undergo or did not qualify for surgical excision or radiotherapy due to inappropriate localization or age. All patients experienced complete tumor regression after a mean of 8.5 weeks (range 3 - 20). Two patients relapsed 4 and 12 months after treatment, respectively, but tumor regression was repeated after additional cycles of intra-lesional IFNalpha2a. All other patients remained free of disease. Thus, intra-lesional IFNalpha2a may represent a valuable alternative to surgery and radiotherapy as first-line treatment of pcMZL.
原发性皮肤边缘区淋巴瘤（pcMZL）属于原发性皮肤B细胞淋巴瘤（pCBCL）组。其特点是局限于皮肤，且在接受各种治疗方式后复发可能性高。一线治疗包括手术和放疗。对于年轻患者或位于面部的pCBCL患者，这些治疗可能并不总是适用，因为手术或放疗可能会留下毁容性疤痕或放射性皮肤损伤。8例pcMZL患者接受每周3次、每次300万单位重组干扰素α2a的皮损内注射治疗。由于病变部位不合适或年龄原因，这些患者要么不想接受手术切除或放疗，要么不符合手术切除或放疗的条件。所有患者在平均8.5周（范围3 - 20周）后均出现肿瘤完全消退。2例患者分别在治疗后4个月和12个月复发，但在额外的皮损内注射干扰素α2a疗程后肿瘤再次消退。所有其他患者均无疾病复发。因此，皮损内注射干扰素α2a可能是pcMZL一线治疗中手术和放疗的一种有价值的替代方法。
